Welcome to our dedicated page for Mannkind SEC filings (Ticker: MNKD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
MannKind Corporation filings document formal disclosures for a Nasdaq-listed biopharmaceutical company focused on inhaled and drug-device therapies. Its 8-K reports furnish operating results and business updates for Afrezza, Furoscix and pipeline programs, while also recording capital-structure events such as convertible-note settlement and material collaboration agreements involving the Technosphere platform.
The filing record also includes acquisition-related disclosures for the completed scPharma transaction, including acquired-business financial statements and pro forma combined financial information. MannKind proxy materials address annual meeting matters, executive compensation and equity-award information, and other governance subjects tied to its common stock.
MannKind Corp ownership disclosure: State Street Corporation reports beneficial ownership of 18,683,483 shares of Common Stock, representing 6.1% of the class. The filing lists shared voting power of 17,967,218 and shared dispositive power of 18,683,483, with certain holdings attributed to State Street affiliates.
MANNKIND CORP Chief Executive Officer Michael Castagna filed an amended insider report clarifying that a previously filed Form 4 was erroneous. The earlier Form 4 had mistakenly shown him directly acquiring 100,000 MannKind common shares on March 10, 2026.
The amendment explains these shares were actually acquired by his spouse in a segregated retirement account in which he has no pecuniary interest, so the transaction should not be attributed to him and the prior Form 4 should be deemed revoked. As of March 10, 2026, he is reported as directly owning 2,475,911 MannKind common shares.
MannKind Corporation reported a net loss for the quarter ended March 31, 2026 despite higher revenue. Total revenues rose to $90.2 million from $78.4 million, driven by commercial product sales of $33.9 million, collaborations and services of $23.5 million, and royalties of $32.7 million.
Total expenses increased to $91.8 million, including higher research and development and selling, general and administrative costs, leading to a loss from operations of $1.7 million. After $14.7 million in net other expense, MannKind recorded a net loss of $16.6 million, or $0.05 per basic and diluted share. Cash, cash equivalents and restricted cash were $53.6 million, with total assets of $744.4 million and total liabilities of $803.6 million, resulting in stockholders’ deficit of $59.2 million.
MannKind Corporation reported a net loss for the quarter ended March 31, 2026 despite higher revenue. Total revenues rose to $90.2 million from $78.4 million, driven by commercial product sales of $33.9 million, collaborations and services of $23.5 million, and royalties of $32.7 million.
Total expenses increased to $91.8 million, including higher research and development and selling, general and administrative costs, leading to a loss from operations of $1.7 million. After $14.7 million in net other expense, MannKind recorded a net loss of $16.6 million, or $0.05 per basic and diluted share. Cash, cash equivalents and restricted cash were $53.6 million, with total assets of $744.4 million and total liabilities of $803.6 million, resulting in stockholders’ deficit of $59.2 million.
MannKind Corporation reported first quarter 2026 total revenues of 90,171 (in thousands), up 15% from 78,354 (in thousands) a year earlier, driven mainly by Furoscix and higher royalties from Tyvaso DPI. Furoscix net sales were 15,493 (in thousands), while Afrezza net sales were 15,273 (in thousands).
Despite revenue growth, MannKind recorded a net loss of 16,619 (in thousands) versus net income of 13,158 (in thousands) in 2025 as cost of goods sold, research and development, and selling, general and administrative expenses all rose sharply, including amortization of acquired intangibles. The company highlighted upcoming PDUFA dates for Afrezza pediatrics and the Furoscix ReadyFlow Autoinjector, progress of MNKD-201 into Phase 2, an expanded ralinepag DPI collaboration with a 5,000 (in thousands) payment and up to 35,000 (in thousands) in potential milestones, and cash, cash equivalents and investments totaling 134 million as of March 31, 2026.
MannKind Corporation reported first quarter 2026 total revenues of 90,171 (in thousands), up 15% from 78,354 (in thousands) a year earlier, driven mainly by Furoscix and higher royalties from Tyvaso DPI. Furoscix net sales were 15,493 (in thousands), while Afrezza net sales were 15,273 (in thousands).
Despite revenue growth, MannKind recorded a net loss of 16,619 (in thousands) versus net income of 13,158 (in thousands) in 2025 as cost of goods sold, research and development, and selling, general and administrative expenses all rose sharply, including amortization of acquired intangibles. The company highlighted upcoming PDUFA dates for Afrezza pediatrics and the Furoscix ReadyFlow Autoinjector, progress of MNKD-201 into Phase 2, an expanded ralinepag DPI collaboration with a 5,000 (in thousands) payment and up to 35,000 (in thousands) in potential milestones, and cash, cash equivalents and investments totaling 134 million as of March 31, 2026.
MannKind Corp Chief Financial Officer Christopher B. Prentiss reported a routine tax-withholding share disposition. On April 22, 2026, 12,267 shares of common stock at $2.74 per share were withheld to cover taxes on Restricted Stock Units that vested from a grant dated May 15, 2024. After this, he directly held 338,924 shares, including 2,337 shares acquired through the Employee Stock Purchase Plan on December 31, 2025.
MannKind Corporation is asking stockholders to vote at its 2026 Annual Meeting, held virtually on May 20, 2026, on three key items: electing nine directors, approving executive pay on an advisory basis, and ratifying Deloitte & Touche LLP as auditor for 2026.
Stockholders of record on March 23, 2026, when 308,795,777 common shares were outstanding, may vote online before or during the meeting. The Board unanimously recommends voting FOR all director nominees, FOR the say‑on‑pay proposal, and FOR Deloitte’s ratification.
The proxy describes MannKind’s governance structure, including an independent chair, fully independent board committees, an anti‑corruption and insider‑trading policy, and director stock ownership guidelines. Non‑employee directors receive cash retainers plus annual restricted stock unit awards that generally vest immediately but are delivered after board service ends.
MannKind Corp — Amendment No. 4 to a Schedule 13G/A filed by The Vanguard Group reports beneficial ownership of 0 shares representing 0% of Common Stock. The filing notes an internal realignment effective January 12, 2026 under SEC Release No. 34-39538 that prompted disaggregated reporting by certain Vanguard subsidiaries. The report is signed by Ashley Grim on March 27, 2026, and states Vanguard entities have the right to receive dividends or proceeds for managed accounts, while no single outside person holds more than 5%.
MannKind Corp’s Chief Financial Officer Christopher B. Prentiss received new equity awards. He was granted 221,000 performance-based restricted stock units, each representing a right to one share of common stock, and 217,000 employee stock options with a $2.44 exercise price, all held directly.
The performance units vest on January 15, 2029, with actual payout from 0% to 300% of the 221,000-share target based on MannKind’s total shareholder return from April 1, 2026 through December 31, 2028 versus the Russell 3000 Pharmaceutical & Biotechnology Index. The options vest 25% on March 23, 2027 and then 1/16 quarterly until fully vested, and expire on March 23, 2036.
MannKind Corp Chief Executive Officer Michael Castagna received new equity compensation awards. He was granted 796,000 performance-based restricted stock units, each representing the right to receive one share of common stock. The actual shares that vest on January 15, 2029 can range from 0% to 300% of this target, based on MannKind’s total shareholder return from April 1, 2026 to December 31, 2028 versus the Russell 3000 Pharmaceutical & Biotechnology Index.
He was also granted stock options for 782,000 shares of common stock at an exercise price of $2.4400 per share, expiring on March 23, 2036. These options vest 25% on March 23, 2027 and the remaining portion in equal quarterly installments over four years.